MedCity News - The acquisition brings Amgen a novel Phase 3-ready drug for gastric cancers. For Five Prime Therapeutics, the deal is a lifeline following a series...
MedCity News - The acquisition brings Amgen a novel Phase 3-ready drug for gastric cancers. For Five Prime Therapeutics, the deal is a lifeline following a series...
.@Amgen's $1.9B @FivePrime_FPRX deal adds to #cancer #drug pipeline and Asia strategy, writes @frankvinluan @medcitynews. For Five Prime Therapeutics, the deal is a lifeline following a series of clinical and financial setbacks. #biopharma #therapies https://t.co/yqtZYB90wG